Faron Pharmaceuticals Ltd
Privately held: no public share price
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Clever-1Monoclonal antibody | Non-Small Cell Lung CancerAcute Myeloid LeukemiaMyelodysplastic Syndromes Higher-Risk Myelodysplastic Syndromes |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
March 2027 (1)
What to watch
November 2027 (1)
What to watch
Financial reports
Quarterly & interim (4)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $0 | $7.8M | $16M | — | report ↗ |
Faron reported revenue of $0M, unchanged YoY, with R&D spend of $7.77M, up 7.8% YoY, and cash and equivalents of $15.87M. The company posted an operating loss of EUR 11.9 million for H1 2025 and a loss per share of EUR 0.18; net income was not disclosed.
Faron does not provide a short-term outlook. During the period, bexmarilimab progressed with full enrollment of the BEXMAB phase II dose optimization and phase I/II frontline HR-MDS studies, positive phase II efficacy data presented at major oncology congresses, and publication of phase I BEXMAB data in Lancet Haematology. EMA and FDA granted orphan drug designation for bexmarilimab in MDS. After period end, FDA end-of-phase II feedback supported advancement into a registrational phase II/III study in frontline HR-MDS with CR+CReq as primary and overall survival as co-primary endpoints. Financially, an oversubscribed EUR 12M private placement and an up to EUR 35M convertible bond arrangement (first tranche EUR 15M) extended the cash runway into Q1 2026.
View 3 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-H1 | $0 | $7.2M | $32M | — | report ↗ |
| 2023-H1 | $0 | $9.2M | $6.9M | — | report ↗ |
| 2022-H1 | $0 | $11M | $10M | — | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $14M | $14M | — | report ↗ |